| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1127167840 |
| P356 | DOI | 10.1016/J.PHRS.2020.104859 |
| P932 | PMC publication ID | 7189851 |
| P698 | PubMed publication ID | 32360480 |
| P2093 | author name string | Stefan Laufer | |
| Cord Naujokat | |||
| Ariane Sternberg | |||
| Dwight L McKee | |||
| Ulrike Stange | |||
| P2860 | cites work | The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase | Q21089768 |
| Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection | Q21245138 | ||
| A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry | Q24306622 | ||
| Chloroquine is a potent inhibitor of SARS coronavirus infection and spread | Q24815979 | ||
| Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs | Q27641252 | ||
| Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus | Q28188496 | ||
| ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors | Q28218830 | ||
| The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses | Q28271798 | ||
| Characteristics of arbidol-resistant mutants of influenza virus: implications for the mechanism of anti-influenza action of arbidol | Q28301644 | ||
| ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease | Q28369297 | ||
| Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea | Q28550455 | ||
| Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts | Q28730201 | ||
| Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor | Q30219701 | ||
| The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. | Q30370367 | ||
| T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. | Q30376917 | ||
| Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. | Q30432156 | ||
| The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus | Q89865301 | ||
| The "Big Five" Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein | Q89929789 | ||
| Clinical trial analysis of 2019-nCoV therapy registered in China | Q89931532 | ||
| Structure of Mpro from COVID-19 virus and discovery of its inhibitors | Q89975279 | ||
| In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Q90160332 | ||
| COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease | Q90271816 | ||
| Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study | Q90327975 | ||
| A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19 | Q90335371 | ||
| Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China | Q90356963 | ||
| Use of antiviral drugs to reduce COVID-19 transmission | Q90564226 | ||
| Myricetin inhibits NLRP3 inflammasome activation via reduction of ROS-dependent ubiquitination of ASC and promotion of ROS-independent NLRP3 ubiquitination | Q90807416 | ||
| Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis: a multicenter, randomized, open-label, phase 2 trial | Q91406418 | ||
| A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics | Q91489202 | ||
| An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice | Q91610063 | ||
| Dietary Apigenin Reduces Induction of LOX-1 and NLRP3 Expression, Leukocyte Adhesion, and Acetylated Low-Density Lipoprotein Uptake in Human Endothelial Cells Exposed to Trimethylamine-N-Oxide | Q91799822 | ||
| Compassionate Use of Remdesivir for Patients with Severe Covid-19 | Q91807066 | ||
| Cepharanthine: An update of its mode of action, pharmacological properties and medical applications | Q92318984 | ||
| Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial | Q92333096 | ||
| A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC) | Q92622047 | ||
| Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 | Q93221320 | ||
| Medication for COVID-19-an Overview of Approaches Currently Under Study | Q94445462 | ||
| Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor | Q82697155 | ||
| Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction | Q83859739 | ||
| Novel peptide inhibitors of angiotensin-converting enzyme 2. | Q31133376 | ||
| Baicalin, a metabolite of baicalein with antiviral activity against dengue virus | Q33807926 | ||
| Arbidol as a broad-spectrum antiviral: an update | Q34040731 | ||
| Effect of a Specific Serine Protease Inhibitor on the Rat Pancreas: Systemic Administration of Camostate and Exocrine Pancreatic Secretion | Q34250533 | ||
| Protease inhibitors targeting coronavirus and filovirus entry | Q34461982 | ||
| Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys | Q34516555 | ||
| Kaletra (lopinavir/ritonavir). | Q34709832 | ||
| Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response | Q35076795 | ||
| Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. | Q35536588 | ||
| Species-specific inhibitor sensitivity of angiotensin-converting enzyme 2 (ACE2) and its implication for ACE2 activity assays | Q35543390 | ||
| Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry | Q36086649 | ||
| Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. | Q36185540 | ||
| Effective inhibition of MERS-CoV infection by resveratrol | Q36279084 | ||
| Global patterns in coronavirus diversity | Q36409901 | ||
| Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats | Q37084921 | ||
| Baicalin suppresses NLRP3 inflammasome and nuclear factor-kappa B (NF-κB) signaling during Haemophilus parasuis infection | Q37160312 | ||
| Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. | Q37358618 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. | Q38665457 | ||
| Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses | Q38787797 | ||
| Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking | Q39104403 | ||
| Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases | Q39360987 | ||
| In vitro and in vivo activities of anti-influenza virus compound T-705. | Q39651429 | ||
| TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds | Q39765671 | ||
| Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase | Q40044875 | ||
| GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses | Q40066603 | ||
| Identification of critical active-site residues in angiotensin-converting enzyme-2 (ACE2) by site-directed mutagenesis | Q40399203 | ||
| Nicotianamine is a novel angiotensin-converting enzyme 2 inhibitor in soybean | Q40803618 | ||
| Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset | Q41096904 | ||
| The serine protease inhibitor camostat inhibits influenza virus replication and cytokine production in primary cultures of human tracheal epithelial cells. | Q41112381 | ||
| Protease inhibitor therapy for recessive dystrophic epidermolysis bullosa. In vitro effect and clinical trial with camostat mesylate | Q41438269 | ||
| Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing | Q41454044 | ||
| In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine | Q41913526 | ||
| Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model | Q43194438 | ||
| Efficacy of camostat mesilate against dyspepsia associated with non-alcoholic mild pancreatic disease | Q43252092 | ||
| Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients | Q43896562 | ||
| Role of nicotianamine in the intracellular delivery of metals and plant reproductive development | Q44463085 | ||
| Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor | Q45113065 | ||
| Quercetin and Ascorbic Acid Suppress Fructose-Induced NLRP3 Inflammasome Activation by Blocking Intracellular Shuttling of TXNIP in Human Macrophage Cell Lines | Q46399998 | ||
| Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2. | Q46715393 | ||
| New insights into the antiviral effects of chloroquine. | Q46913485 | ||
| Mefloquine for preventing malaria during travel to endemic areas | Q47140318 | ||
| Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB and NLRP3 inflammasome activation | Q47952976 | ||
| Luteolin alleviates NLRP3 inflammasome activation and directs macrophage polarization in lipopolysaccharide-stimulated RAW264.7 cells | Q50105828 | ||
| Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. | Q52316040 | ||
| Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. | Q53703208 | ||
| Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. | Q53704198 | ||
| Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities | Q58616077 | ||
| Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 | Q58785257 | ||
| Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome | Q61807081 | ||
| Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir | Q64359892 | ||
| Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses | Q64360387 | ||
| Antiviral Efficacy of Flavonoids against Enterovirus 71 Infection in Vitro and in Newborn Mice | Q66679210 | ||
| Plasma Collection Using Nafamostat Mesilate and Dipyridamole as an Anticoagulant | Q68467529 | ||
| Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on the pancreatic enzymes and experimental acute pancreatitis in rats | Q68971878 | ||
| Stimulation of pancreatic secretion in man by a protease inhibitor (camostate) | Q70387470 | ||
| Effect of the synthetic protease inhibitor [N,N-dimethylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on carcinogenesis by 3-methylcholanthrene in mouse skin | Q70921966 | ||
| Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma | Q70953211 | ||
| Structural insights into coronavirus entry | Q84315921 | ||
| Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro | Q84360011 | ||
| A Novel Coronavirus from Patients with Pneumonia in China, 2019 | Q86729469 | ||
| Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding | Q86735535 | ||
| Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies | Q86824600 | ||
| The outbreak of COVID-19 | Q87226482 | ||
| An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov) | Q87461382 | ||
| Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection | Q87461568 | ||
| Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial | Q87908797 | ||
| Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein | Q87973551 | ||
| Genetic evolution analysis of 2019 novel coronavirus and coronavirus from other species | Q88197712 | ||
| Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors | Q88219766 | ||
| SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor | Q88292103 | ||
| A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | Q88370045 | ||
| Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV | Q88486711 | ||
| Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model | Q88486730 | ||
| Flavonoids interfere with NLRP3 inflammasome activation | Q89361879 | ||
| Virological assessment of hospitalized patients with COVID-2019 | Q89379643 | ||
| Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV | Q89542749 | ||
| P921 | main subject | COVID-19 | Q84263196 |
| SARS-CoV-2 | Q82069695 | ||
| P304 | page(s) | 104859 | |
| P577 | publication date | 2020-04-29 | |
| 2020-07-01 | |||
| P1433 | published in | Pharmacological Research | Q15724622 |
| P1476 | title | Candidate drugs against SARS-CoV-2 and COVID-19 | |
| P478 | volume | 157 |
| Q104492586 | A retrospective comparison of drugs against COVID-19 |
| Q98200191 | An overview of the pathogenic mechanisms involved in severe cases of COVID-19 infection, and the proposal of salicyl-carnosine as a potential drug for its treatment |
| Q94672277 | Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases |
| Q97644074 | Blood Targets of Adjuvant Drugs Against COVID19 |
| Q98174823 | COVID-19: a complex multisystem disorder |
| Q99547054 | Curcumin, a traditional spice component, can hold the promise against COVID-19? |
| Q97541149 | Deploying Biomolecules as Anti-COVID-19 Agents |
| Q97528635 | Drug targets for COVID-19 therapeutics: Ongoing global efforts |
| Q96343090 | East meets West in COVID-19 therapeutics |
| Q99239990 | Exploration of inhibitory action of Azo imidazole derivatives against COVID-19 main protease (Mpro): A computational study |
| Q100514026 | Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic |
| Q99406885 | Potential use of polyphenols in the battle against COVID-19 |
| Q98178356 | Progress in the Research and Development of Anti-COVID-19 Drugs |
| Q99634159 | Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19 |
| Q108739582 | Structural Analysis of SARS-CoV-2 ORF8 Protein: Pathogenic and Therapeutic Implications |
| Q97519975 | Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination |
| Q99412241 | Synthesis of 3,3'-methylenebis(4-hydroxyquinolin-2(1H)-ones) of prospective anti-COVID-19 drugs |
| Q101235429 | The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies |
| Q110951949 | The Spike Glycoprotein of SARS-CoV-2 Binds to β1 Integrins Expressed on the Surface of Lung Epithelial Cells |
| Q99619188 | The natural way forward: Molecular dynamics simulation analysis of phytochemicals from Indian medicinal plants as potential inhibitors of SARS-CoV-2 targets |
| Q98771813 | Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion |
| Q104522379 | Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2 |
| Q98892268 | [Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia] |
Search more.